Testicular germ cell tumour affects young men most frequently, but thanks to modern medicine, it has become one of the most curable cancers. Treatment aims to remove the tumour completely, prevent its spread, and help patients return to normal life with the best possible quality of life.

Treatment goals and modern approaches to testicular cancer

Testicular germ cell tumours represent a unique challenge in cancer treatment, but they also stand as one of medicine’s greatest success stories. The main goal of treatment is to achieve complete cure while minimising long-term side effects, particularly in young patients who have their whole lives ahead of them. Treatment strategies depend on several factors: the type of tumour, how far it has spread, the patient’s general health, and individual preferences, especially regarding future fertility.^[1]

More than 90% of testicular cancers start in germ cells, which are the cells that normally develop into sperm. These tumours are classified into two main groups: seminomas and non-seminomas. Seminomas typically grow and spread more slowly, while non-seminomas tend to be more aggressive and grow faster. This distinction is crucial because it determines which treatment approach will work best.^[1][6]

The treatment landscape includes several established methods approved by medical societies worldwide. Surgery to remove the affected testicle remains the foundation of treatment. Beyond surgery, patients may receive chemotherapy, which uses powerful medicines to kill cancer cells, or radiation therapy, which uses high-energy rays. Importantly, medical research continues to explore new therapies through clinical trials, offering hope for even better outcomes with fewer side effects in the future.^[11]

What makes testicular germ cell tumours particularly remarkable is their high cure rate. Even though the incidence of these cancers has been rising globally, the survival rates have improved dramatically. For patients with early-stage disease, cure rates approach 100%, and even for those with advanced disease that has spread to other organs, more than 70% can be cured. This stands in stark contrast to many other cancers and represents what doctors call “a miracle of modern medicine.”^[11][15]

Standard treatment approaches

Surgery as the cornerstone of treatment

The primary and most essential treatment for testicular germ cell tumour is surgical removal of the affected testicle, a procedure called orchiectomy or orchidectomy. This operation is performed under general anaesthesia and involves making a small incision in the groin, not the scrotum. Through this incision, the surgeon removes the entire testicle along with the spermatic cord, which is the tube that connects the testicle to the rest of the body. This approach ensures that cancer cells cannot spread through the cord during the procedure.^[9][13]

For many patients with early-stage disease, removing the testicle may be the only treatment needed. After the surgery, patients are monitored carefully with regular check-ups, blood tests, and imaging scans. This approach, called active surveillance, allows doctors to detect any return of the cancer early while sparing patients from additional treatments and their side effects. The removed testicle is sent to a laboratory where specialists examine it under a microscope to determine the exact type of tumour and whether it has invaded blood vessels or nearby structures, information that guides further treatment decisions.^[9]

Patients are typically offered the option to have an artificial testicle, called a testicular prosthesis, inserted during the same operation or at a later date. This prosthesis is made of silicone and is designed to look and feel like a natural testicle. While it serves no medical function, many men choose to have one inserted for cosmetic and psychological reasons. The decision is entirely personal and does not affect cancer treatment or outcomes.^[13]

In rare cases where the cancer has spread extensively to lymph nodes in the abdomen, additional surgery may be necessary. This procedure, called retroperitoneal lymph node dissection, involves removing lymph nodes at the back of the abdomen. It is a complex operation that requires significant surgical expertise. Sometimes this surgery is performed after chemotherapy to remove any remaining masses that might contain residual cancer or dead tumour tissue.^[9]

Chemotherapy for testicular cancer

Chemotherapy plays a central role in treating testicular germ cell tumours, particularly for non-seminomas and advanced seminomas. The most important chemotherapy drug for this cancer is cisplatin, a platinum-based medicine that has revolutionised testicular cancer treatment since its introduction in the 1970s. Testicular germ cell tumours are extraordinarily sensitive to cisplatin, which explains why this cancer has such high cure rates compared to other solid tumours.^[11][15]

The standard chemotherapy regimen combines three drugs: cisplatin, etoposide, and bleomycin, commonly abbreviated as BEP. This combination is given in cycles, with each cycle lasting about three weeks. Most patients receive three or four cycles, depending on the extent of their disease. The medicines are administered through an intravenous line, usually in an outpatient clinic, though some patients may need to stay in hospital for monitoring, especially during the first cycle.^[11]

Another commonly used regimen is EP, which uses only cisplatin and etoposide without bleomycin. This combination may be chosen for patients who have risk factors for lung damage, as bleomycin can cause pulmonary toxicity, a condition where the lungs become scarred and less efficient at transferring oxygen into the blood. Doctors carefully weigh the benefits and risks of including bleomycin based on each patient’s individual circumstances.^[9]

For patients with very advanced disease or those whose cancer returns after initial treatment, more intensive chemotherapy regimens may be necessary. These can include higher doses of the standard drugs or the addition of other agents such as ifosfamide. In some cases, doctors may recommend high-dose chemotherapy followed by stem cell transplantation, where the patient’s own blood stem cells are collected before treatment and then returned after chemotherapy to help the bone marrow recover.^[9]

Side effects of chemotherapy

While chemotherapy is highly effective, it does cause side effects that can affect quality of life during and after treatment. Common short-term side effects include nausea and vomiting, which can usually be controlled with anti-sickness medicines. Hair loss is common with the BEP regimen but is temporary; hair typically starts growing back within a few months after treatment ends. Fatigue is another frequent complaint, and patients often need to reduce their work hours or take time off during treatment.^[12]

Chemotherapy temporarily weakens the immune system by reducing the number of white blood cells, making patients more vulnerable to infections. Patients are advised to monitor their temperature and contact their medical team immediately if they develop a fever, as this could indicate a serious infection requiring urgent antibiotic treatment. Low red blood cell counts can cause anaemia, leading to breathlessness and tiredness, while low platelet counts increase the risk of bruising and bleeding.^[12]

Long-term side effects are a particular concern in testicular cancer survivors because they are typically young when treated and will live many decades after their cancer is cured. Cisplatin can cause permanent damage to hearing, particularly affecting the ability to hear high-pitched sounds. This condition, called ototoxicity, may not be immediately noticeable but can worsen over time. Regular hearing tests are recommended during and after treatment.^[11]

Cisplatin can also cause nerve damage, a condition called peripheral neuropathy, which results in numbness, tingling, or pain in the hands and feet. This typically improves gradually after treatment stops but may persist for years or become permanent in some patients. Kidney function can be affected by cisplatin, which is why patients receive large amounts of intravenous fluids before and after each dose to protect the kidneys. Regular blood tests monitor kidney function throughout treatment.^[11]

Chemotherapy increases the risk of developing other cancers later in life, particularly leukaemia and solid tumours. This risk needs to be balanced against the very high probability of curing the testicular cancer. Cardiovascular problems, including high blood pressure and an increased risk of heart disease, have been observed in long-term survivors treated with chemotherapy. This makes it important for survivors to maintain a healthy lifestyle and have regular medical check-ups even decades after treatment.^[11]

Radiation therapy for seminomas

Radiation therapy is used primarily for treating seminomas, as these tumours are particularly sensitive to radiation. It is rarely used for non-seminomas. The treatment involves directing high-energy X-rays at the lymph nodes in the abdomen where seminoma cells are most likely to have spread. The radiation is delivered by a machine that moves around the patient, focusing the beams precisely on the target area while minimising exposure to surrounding healthy tissues.^[12][13]

A typical course of radiation therapy involves daily treatments, Monday through Friday, for two to three weeks. Each session lasts only a few minutes, and the treatment itself is painless, similar to having an X-ray. Patients lie still on a treatment table while the machine delivers the radiation. Careful planning with CT scans ensures that the radiation is directed accurately to the intended area.^[12]

Side effects from radiation therapy are usually less severe than those from chemotherapy. Common short-term effects include tiredness, which tends to build up gradually over the course of treatment, and digestive problems such as nausea, diarrhoea, or loss of appetite. These symptoms typically improve within a few weeks after treatment ends. Skin in the treated area may become red and sensitive, similar to sunburn, but this also heals relatively quickly.^[12]

Long-term concerns with radiation therapy include a small increased risk of developing other cancers in the treated area, typically appearing many years or decades later. There is also a risk of damage to the remaining testicle if it is not adequately shielded during treatment, which could affect fertility. For this reason, the use of radiation therapy for testicular cancer has declined in recent years, with many centres now preferring chemotherapy or active surveillance for early-stage seminomas.^[13]

Treatment guidelines and duration

International medical societies, including the European Association of Urology and various national cancer organisations, have developed detailed treatment guidelines based on decades of research and clinical experience. These guidelines classify patients into risk groups based on factors such as tumour type, stage, levels of tumour markers in the blood, and which organs the cancer has spread to. This classification system helps doctors recommend the most appropriate treatment for each individual patient.^[10][11]

For good-prognosis patients, which includes most men with early-stage disease, treatment may involve only surgery followed by observation, or surgery plus a short course of chemotherapy. For intermediate-prognosis patients, standard-dose chemotherapy with three or four cycles of BEP is typically recommended. Poor-prognosis patients, who represent a small minority, may require more intensive chemotherapy regimens with four cycles of BEP or alternative combinations.^[10]

The entire treatment process, from diagnosis to the end of active treatment, typically spans three to six months for most patients, though this can vary depending on the stage of disease and chosen treatment approach. After active treatment ends, patients enter a long-term follow-up programme that continues for many years, with gradually decreasing frequency of visits as time passes without recurrence.^[11]

Innovative treatments in clinical trials

Understanding clinical trials

Clinical trials are research studies that test new treatments or new ways of using existing treatments. They are essential for medical progress and for finding better ways to treat cancer with fewer side effects. For testicular germ cell tumours, clinical trials are particularly focused on reducing long-term toxicity while maintaining the excellent cure rates already achieved, as well as finding more effective treatments for the small percentage of patients whose cancer is resistant to standard therapies.^[6]

Clinical trials progress through different phases, each with a specific purpose. Phase I trials test a new treatment in a small group of people for the first time, primarily to evaluate safety, determine a safe dosage range, and identify side effects. Phase II trials involve a larger group of participants and focus on determining whether the treatment is effective against the cancer while continuing to monitor safety. Phase III trials compare the new treatment directly with the current standard treatment in a large group of patients to see if it is better, equally effective, or causes fewer side effects.^[10]

Participation in clinical trials is voluntary, and patients can withdraw at any time. Before joining a trial, patients receive detailed information about what the study involves, potential risks and benefits, and alternative treatments available. This process, called informed consent, ensures that patients understand what they are agreeing to. Not every patient is eligible for every trial; each study has specific criteria regarding cancer stage, previous treatments, overall health, and other factors.^[10]

Reducing treatment intensity for early-stage disease

One major focus of current clinical research is exploring whether patients with early-stage testicular cancer can be treated successfully with less intensive therapy, thereby reducing side effects and improving long-term quality of life. Several trials are investigating whether active surveillance, where patients are monitored closely without immediate additional treatment after surgery, can safely replace chemotherapy or radiation for selected patients with stage I seminoma or non-seminoma.^[10]

For patients who do need chemotherapy, researchers are studying whether one or two cycles of treatment might be sufficient instead of the traditional three or four cycles. Early results from some studies suggest that carefully selected patients with good-prognosis disease might achieve the same cure rates with less treatment, potentially reducing the risk of long-term side effects such as hearing loss, nerve damage, and cardiovascular problems that are associated with cumulative cisplatin exposure.^[11]

Another area of investigation involves identifying biomarkers that can predict which patients are at highest risk of recurrence and therefore need more intensive treatment, and which patients have such low risk that they can safely avoid additional therapy after surgery. These biomarkers might include specific genetic mutations in the tumour, patterns of gene expression, or particular characteristics seen under the microscope. If successful, this approach would allow truly personalised treatment tailored to each patient’s individual cancer.^[6]

New approaches for resistant or relapsed disease

While the majority of testicular cancer patients are cured with standard treatment, approximately 5-10% of patients have disease that is resistant to chemotherapy or that comes back after initial treatment. For these patients, new therapeutic approaches are desperately needed. Several innovative treatments are being explored in clinical trials specifically for this group.^[11][15]

High-dose chemotherapy followed by autologous stem cell transplantation is being studied as a salvage therapy for patients whose cancer has relapsed. In this approach, doctors collect the patient’s own blood-forming stem cells before administering extremely high doses of chemotherapy that would normally destroy the bone marrow. After the chemotherapy, the stored stem cells are returned to the patient, where they travel to the bone marrow and restore its ability to produce blood cells. While this approach is intensive and carries significant risks, it offers hope for patients who have run out of other options.^[9]

Researchers are investigating new chemotherapy drugs and combinations for patients with cisplatin-resistant disease. Some trials are testing drugs that work through different mechanisms than cisplatin, potentially overcoming resistance. Others are exploring drugs that can make cancer cells more sensitive to chemotherapy, called chemosensitisers. These agents might work by interfering with the cancer cells’ ability to repair DNA damage or by blocking pathways that allow cells to resist the effects of chemotherapy drugs.^[15]

Immunotherapy and targeted therapies

Immunotherapy, which harnesses the power of the patient’s own immune system to fight cancer, has revolutionised treatment for many types of cancer. However, testicular germ cell tumours have proven more challenging for immunotherapy approaches. These cancers often have relatively few mutations compared to other cancers, which may make them less visible to the immune system. Nevertheless, researchers continue to explore whether immunotherapy might benefit certain subgroups of patients.^[15]

Checkpoint inhibitors are a type of immunotherapy that removes the “brakes” on immune cells, allowing them to recognise and attack cancer cells more effectively. Drugs such as pembrolizumab and nivolumab, which target a checkpoint protein called PD-1, are being tested in clinical trials for patients with testicular cancer that has not responded to chemotherapy. Early results have been mixed, with some patients experiencing responses but many not benefiting. Researchers are working to identify which patients are most likely to respond to these treatments.^[10]

Targeted therapies are treatments designed to attack specific molecular abnormalities in cancer cells while sparing normal cells. Research has identified some genetic changes that occur frequently in testicular germ cell tumours, including gains of chromosome 12p. Scientists are investigating whether drugs that target pathways affected by these genetic changes might be effective treatments. This includes inhibitors of specific enzymes or signalling molecules that cancer cells depend on for growth and survival.^[4][6]

Understanding the unique biology of germ cell tumours

Testicular germ cell tumours contain cells that are remarkably similar to embryonic stem cells, which are cells in early development that can potentially become any cell type in the body. This characteristic, called pluripotency, is unique among solid tumours and may explain both why these cancers are so sensitive to chemotherapy and why they have such a good prognosis. Researchers are studying the molecular mechanisms that maintain pluripotency in these tumour cells to identify new treatment targets.^[15]

The stem cell component of non-seminoma testicular cancer is called embryonal carcinoma. These cells express specific proteins that are normally found only in embryonic stem cells, such as OCT4 and NANOG. Scientists are investigating whether drugs that interfere with these proteins could selectively kill cancer stem cells while leaving normal cells unharmed. This approach could potentially lead to new treatments with fewer side effects than conventional chemotherapy.^[15]

Interestingly, testicular germ cell tumours have a very low rate of genetic mutations compared to most other cancers, yet they often have abnormal numbers of whole chromosomes, a condition called aneuploidy. Nearly all testicular germ cell tumours have extra copies of part or all of chromosome 12. Researchers are working to understand how these chromosomal abnormalities contribute to cancer development and whether they represent vulnerabilities that could be exploited for treatment.^[4][6]

Clinical trial locations and eligibility

Clinical trials for testicular cancer are conducted at major cancer centres around the world, including in Europe, the United States, and other countries. Many trials are multi-centre studies, meaning they involve multiple hospitals working together, which allows researchers to enrol enough patients to answer their questions even for this relatively rare cancer. Patients interested in clinical trials can discuss options with their oncologist, who can help identify suitable trials and facilitate referral if appropriate.^[10]

Eligibility for clinical trials depends on many factors, including the stage and type of testicular cancer, previous treatments received, overall health status, and specific criteria set by each study. Some trials are only open to patients who have never received treatment, while others specifically recruit patients whose cancer has relapsed or not responded to standard therapy. Age, organ function, and the presence of other medical conditions also affect eligibility. Trial coordinators carefully review each potential participant’s medical history to ensure they meet all criteria before enrolment.^[10]

Most common treatment methods

• Surgery
  • Orchiectomy or orchidectomy: removal of the affected testicle through an incision in the groin, which may be the only treatment needed for early-stage disease
  • Retroperitoneal lymph node dissection: surgical removal of lymph nodes at the back of the abdomen when cancer has spread to these areas
  • Option for testicular prosthesis insertion for cosmetic purposes
  • Post-chemotherapy surgery to remove residual masses that may contain dead tumour tissue or remaining cancer cells
• Chemotherapy
  • BEP regimen: combination of bleomycin, etoposide, and cisplatin given over three or four cycles for most patients with advanced disease
  • EP regimen: cisplatin and etoposide without bleomycin, used for patients at risk of lung damage
  • Cisplatin-based protocols that have made testicular cancer one of the most curable solid tumours
  • High-dose chemotherapy with stem cell transplantation for patients with resistant or relapsed disease
• Radiation therapy
  • External beam radiation targeting abdominal lymph nodes, used primarily for seminomas
  • Daily treatments over two to three weeks delivered as an outpatient procedure
  • Precise targeting using CT scan planning to minimise exposure to healthy tissues
  • Less commonly used now due to long-term concerns and availability of effective alternatives
• Active surveillance
  • Close monitoring with regular examinations, blood tests for tumour markers, and imaging scans
  • Used for carefully selected patients with early-stage disease after surgical removal of the testicle
  • Allows detection of recurrence early while avoiding treatment side effects
  • Requires patient commitment to attending all scheduled follow-up appointments
• Immunotherapy (in clinical trials)
  • Checkpoint inhibitors such as pembrolizumab and nivolumab being tested for resistant disease
  • Treatments that remove brakes on the immune system to help it recognise and attack cancer cells
  • Currently being studied primarily for patients whose cancer has not responded to chemotherapy
  • Results have been mixed, with ongoing research to identify patients most likely to benefit
• Targeted therapies (in development)
  • Drugs designed to attack specific molecular abnormalities such as chromosome 12p gains
  • Inhibitors of enzymes and signalling pathways that cancer cells depend on
  • Treatments targeting proteins specific to embryonic stem cells like OCT4 and NANOG
  • Research focused on exploiting unique biological features of germ cell tumours